Xu, T., Li, J., Wang, J., Deng, Y., Meng, Q., Niu, Z., Fan, N., Yuan, X., Deng, J., Fang, X., Zhang, Y., Tian, H., Liu, W., Shen, L. (2026). A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated
                    <i>BRAF</i>
                    <sup>V600E</sup>
                    -mutant metastatic colorectal cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba3509